OTTAVA launches as a differentiated, table-integrated robotic surgery platform with FDA approval, targeting global expansion and aiming to transform OR efficiency and workflow. Early clinical data show high satisfaction and procedural success, with ongoing innovation and market growth expected.Base…
Johnson & Johnson (NYSE:JNJ) shares are edging higher on Friday as investors digest two major biotech pipeline moves.What Is Johnson & Johnson’s Latest Biotech Acquisition?Johnson & Johnson is expanding its biotech portfolio with a $1 billion cash acquisition of Firefly Bio Inc. and a partnership w…
Johnson & Johnson announced a proposed $5.5 billion resolution of remaining ovarian talc claims with first payment of up to $3 billion in 2027, conditioned on ~95% claim participation.Key Highlights:Original SEC Filing: JOHNSON & JOHNSON [ JNJ ] - 8-K - Jul. 27, 2026This is an AI-powered summary. I…
Johnson & Johnson (JNJ) said on Monday it had reached an agreement with plaintiffs' lawyers on a proposed resolution of the remaining U.S. lawsuits alleging its talc products caused ovarian cancer, committing $5.5 billion to settle around 76,000 claims.The healthcare company said the agreement cove…
Issued on behalf of Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP)NEW YORK and TORONTO, July 21, 2026 /CNW/ -- USA News Group - News Commentary - Depression remains one of the most stubborn problems in modern medicine, and the numbers behind it are staggering. Tens of millions of adults live with major…
Johnson & Johnson (NYSE: JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare professionals in the U.S., selected by Johnson & Johnson and a panel of industry experts, whose care, innovation and grit are driving health s…
DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced it has acquired Expanding Innovations, Inc., an emerging leader in expandable implant technology for spine surgery. The transaction strengthens DePuy Synthes’ Spine portfolio and expands its position in the ra…
Shares of Sellas Life Sciences (SLS) and ImmunityBio (IBRX) climbed overnight heading into Thursday as retail traders hunted for Big Pharma’s next oncology target after Johnson & Johnson doubled down on acquisitions and its goal of becoming the world’s No. 1 cancer-drug company.In overnight trading…
Q2 2026 saw 5.6% operational sales growth to $25.3B, with double-digit growth excluding STELARA. Full-year guidance was raised, driven by strong Innovative Medicine and MedTech launches, robust pipeline momentum, and continued margin discipline.Based on Johnson & Johnson [JNJ] Q2 2026 Audio Transcr…
Q2 2026 saw 6.6% sales growth to $25.3B and adjusted EPS up to $2.90, with strong performance in oncology, immunology, and MedTech. Full-year guidance was raised for both sales and adjusted EPS, while significant product approvals and pipeline advancements were achieved.Original document: Johnson…
Q2 2026 saw 6.6% sales growth to $25.3B and adjusted EPS up 4.7% to $2.90, driven by innovation and strong performance in Innovative Medicine and MedTech. Full-year guidance was raised, with operational sales growth expected at 6.8% and key pipeline milestones ahead.Original document: Johnson & Joh…
JNJ (Johnson & Johnson) is set to announce its Q2'26 results on July 15, after the market closes. The earnings are expected to be disclosed at 6:45 AM ET (10:45 AM UTC).For Q2'26, revenue estimate is 25.02 billion USD with EPS (earnings per share) anticipated at 2.85 USD. Learn more details at JNJ…
Vertex Pharmaceuticals NASDAQ:VRTX has agreed to buy Crinetics Pharmaceuticals NASDAQ:CRNX for about $10 billion, expanding its reach beyond blood disorders and pain into rare endocrine diseases.The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical…
By Paul R. La MonicaNervous about all the volatility in semiconductor stocks and the broader tech sector? Healthcare stocks might offer some safety.The sector boasts steady dividends, solid fundamentals, and the potential for a boost from more merger activity, especially among smaller biotechs. And…
Johnson & Johnson's JNJ MedTech division, which includes orthopedics, surgery, cardiovascular, electrophysiology, vision and wound closure products, contributes roughly 36% to the company’s total revenues.J&J is repositioning its MedTech portfolio toward more innovative, faster-growing areas, most…
Regulatory scrutiny of Johnson & Johnson (NYSE:JNJ) intensified as the FTC filed an amicus brief accusing the company of anticompetitive drug practices, even as J&J reported promising trial results for its investigational antibody IMAAVY (nipocalimab) in generalized myasthenia gravis, a development…
Navan (NAVN), Johnson & Johnson (JNJ), and CrowdStrike Holdings (CRWD) stocks climbed to fresh 52-week highs on Thursday, as investors turned cautious ahead of the Independence Day holiday weekend, stepping away from risk assets and focusing on company-specific developments.Navan and Johnson & John…
Johnson & Johnson JNJ and AbbVie ABBV are among the world's leading drugmakers, with strong franchises in immunology, oncology and neuroscience. In addition to these core therapeutic areas, J&J has a broad portfolio spanning cardiovascular and metabolic diseases, pulmonary hypertension and infectio…
By Kunal Das and Kamal ChoudhuryThe U.S. Food and Drug Administration said on Tuesday it has approved Orca Bio's therapy for the treatment of certain blood cancers, which also aims to lower the risk of stem cell transplant complications.The therapy, called Orca-T, brand name Tregzi, aims to treat p…
The U.S. Food and Drug Administration has approved Orca Bio's cell therapy for the treatment of certain blood cancers, the regulator said on Tuesday.
